Ryan Malcolm Hum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Malcolm Hum has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Anne Barton
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester , Manchester
7 shared publications Pauline Ho
The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
7 shared publications- Darren Plant
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester , Manchester
4 shared publications - Pauline Ho
Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
4 shared publications - John Bowes
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
3 shared publications - Sebastien Viatte
Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
3 shared publications
Latest Publications
- Open Access
Redefining Synovial Pathotypes in Psoriatic Arthritis through Multi-Modal Histology and Machine Learning (The PSYNOVIUM Study)
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.
Open AccessRedefining Synovial Pathotypes in Psoriatic Arthritis through Multi-Modal Histology and Machine Learning (The PSYNOVIUM Study)
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.
- Open Access
- 7 November 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (4)
Synovial and serum S100A4 expression in rheumatoid arthritis is observed across disease stages and synovial pathotypes
- 7 November 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (4)
Open AccessSynovial and serum S100A4 expression in rheumatoid arthritis is observed across disease stages and synovial pathotypes
- Open Access
Recruitment Success Among Ethnic Minority Doctors and International Medical Graduates in UK Medical Specialty Recruitment: A Repeated Cross-Sectional Analysis of NHS England Data (2021–2025)
Background: Ethnic minority doctors and international medical graduates (IMGs) now make up most applicants to UK specialty training. Earlier work has reported lower recruitment success for some ethnic groups, but evidence that covers recent cycles, every training level, all recruitment stages and disaggregated ethnic groups is limited. We describe trends in ethnicity and country of primary medical qualification among applicants to UK specialty training between 2021 and 2025, and compare the odds of receiving a training offer between groups. Methods: Repeated cross-sectional analysis of national specialty recruitment data published by NHS England for 2021–2025, comprising 328,839 applications to entry-level (ST1/CT1) and higher specialty (ST3+) programmes. Unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) for receiving an offer were calculated for each programme with at least 500 cumulative offers, comparing broad ethnic groups with White applicants, sub-ethnic groups within broad groups, and EU/EEA and rest-of-world graduates with UK graduates. Spearman’s rank correlation tested whether programmes with more rest-of-world applicants showed larger ethnic differences. Ethnicity offers for 2023 were excluded because the published 2023 tables duplicate those for 2021. Results: Applications rose 3.1-fold, from 36,709 in 2021 to 114,557 in 2025, while annual offers stayed between 16,988 and 19,710. The share of applications from White applicants fell from 34.9% to 16.0%, and the share from doctors qualifying outside the UK and EU rose from 43.9% to 69.4%. Asian and Black applicants had lower offer odds than White applicants in every programme analysed (9 entry-level and 12 higher programmes), with the largest differences at entry level in Anaesthetics (Black vs White OR 0.027, 95% CI 0.020–0.036) and Emergency Medicine (Asian vs White OR 0.086, 95% CI 0.075–0.098). Chinese applicants had lower odds in 4 of 9 entry-level and 1 of 12 higher programmes. Within broad groups, Pakistani and Bangladeshi applicants had lower odds than Indian applicants, and Black Caribbean applicants higher odds than Black African applicants, at both levels. Rest-of-world graduates had lower odds than UK graduates in all 11 entry-level and 17 higher programmes. A programme’s share of rest-of-world applicants was not significantly correlated with Asian or Black offer ORs ( ρ − 0.45 to − 0.27; all p ≥ 0.22). Conclusions: Centralised medical recruitment in the UK exhibits some persistent ethnic and international qualification disparities despite rising application diversity. The findings highlight the necessity of disaggregating ethnic groups and addressing subjective evaluation vulnerabilities within multi-stage recruitment processes to foster equity.
Open AccessRecruitment Success Among Ethnic Minority Doctors and International Medical Graduates in UK Medical Specialty Recruitment: A Repeated Cross-Sectional Analysis of NHS England Data (2021–2025)
Background: Ethnic minority doctors and international medical graduates (IMGs) now make up most applicants to UK specialty training. Earlier work has reported lower recruitment success for some ethnic groups, but evidence that covers recent cycles, every training level, all recruitment stages and disaggregated ethnic groups is limited. We describe trends in ethnicity and country of primary medical qualification among applicants to UK specialty training between 2021 and 2025, and compare the odds of receiving a training offer between groups. Methods: Repeated cross-sectional analysis of national specialty recruitment data published by NHS England for 2021–2025, comprising 328,839 applications to entry-level (ST1/CT1) and higher specialty (ST3+) programmes. Unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) for receiving an offer were calculated for each programme with at least 500 cumulative offers, comparing broad ethnic groups with White applicants, sub-ethnic groups within broad groups, and EU/EEA and rest-of-world graduates with UK graduates. Spearman’s rank correlation tested whether programmes with more rest-of-world applicants showed larger ethnic differences. Ethnicity offers for 2023 were excluded because the published 2023 tables duplicate those for 2021. Results: Applications rose 3.1-fold, from 36,709 in 2021 to 114,557 in 2025, while annual offers stayed between 16,988 and 19,710. The share of applications from White applicants fell from 34.9% to 16.0%, and the share from doctors qualifying outside the UK and EU rose from 43.9% to 69.4%. Asian and Black applicants had lower offer odds than White applicants in every programme analysed (9 entry-level and 12 higher programmes), with the largest differences at entry level in Anaesthetics (Black vs White OR 0.027, 95% CI 0.020–0.036) and Emergency Medicine (Asian vs White OR 0.086, 95% CI 0.075–0.098). Chinese applicants had lower odds in 4 of 9 entry-level and 1 of 12 higher programmes. Within broad groups, Pakistani and Bangladeshi applicants had lower odds than Indian applicants, and Black Caribbean applicants higher odds than Black African applicants, at both levels. Rest-of-world graduates had lower odds than UK graduates in all 11 entry-level and 17 higher programmes. A programme’s share of rest-of-world applicants was not significantly correlated with Asian or Black offer ORs ( ρ − 0.45 to − 0.27; all p ≥ 0.22). Conclusions: Centralised medical recruitment in the UK exhibits some persistent ethnic and international qualification disparities despite rising application diversity. The findings highlight the necessity of disaggregating ethnic groups and addressing subjective evaluation vulnerabilities within multi-stage recruitment processes to foster equity.
- Open Access
- 8 September 2026
- Published by Springer Nature in BMC Medical Education
Sexual minority representation and recruitment success across medical specialities in the United Kingdom: a longitudinal analysis of NHS England data (2021–2024)
Background: Promoting equality, diversity, and inclusion (EDI) within the NHS is a key priority. While international literature suggests sexual minority individuals may be disproportionately represented in certain medical specialties, this has only been explored via questionnaires and surveys in UK postgraduate training, and not in a large, longitudinal study. This study mapped sexual minority representation across UK specialties and evaluated whether recruitment outcomes differ significantly from heterosexual counterparts. Methods: A longitudinal cohort analysis was conducted using NHS England recruitment data (2021–2024). Specialties with fewer than 500 total observations were excluded due to data suppression. Sexual minority proportions were calculated at three recruitment stages: application, offer, and acceptance. Recruitment equity was assessed using Odds Ratios (ORs) with 95% Confidence Intervals (CIs) to compare the odds of receiving an offer between sexual minority and heterosexual applicants ( p < 0.05). Results: Of 214,415 applications, 4% ( n = 7,751) identified as a sexual minority. Sexual minority applicants received 5% of offers ( n = 3,734) and accepted 5% of posts ( n = 2,740). Marked variation occurred between specialties. At entry level (ST1), sexual minority applicant proportions were highest in community sexual and reproductive health (9%), public health (7%), and histopathology (6%), and lowest in cardiothoracic surgery (2%), general practice (2%), and clinical radiology (3%). At higher level (ST3), psychiatry subspecialties (7%) and anaesthetics (5%) showed the highest representation, whereas acute internal medicine (1%) and trauma and orthopaedic surgery (1%) showed the lowest. Of the 32 specialities included after removing 21 specialities with fewer than 500 total offers, sexual minority applicants were not disadvantaged in obtaining offers. At entry level (ST1), sexual minority applicants had significantly higher odds of receiving offers in multiple specialties, notably for core psychiatry training (OR 3.4, 95% CI 3.0–4.0). At higher level (ST3), sexual minority applicants had significantly higher odds of receiving offers in acute internal medicine, haematology, trauma and orthopaedic surgery, and clinical oncology. Conclusion: UK recruitment processes provide an equitable gateway for sexual minority doctors, showing no systemic bias in offer rates. However, marked variation in representation suggests cultural perceptions or self-selection may influence career choices, highlighting a need to investigate potential structural barriers in low-representation specialties.
- 8 September 2026
- Published by Springer Nature in BMC Medical Education
Open AccessSexual minority representation and recruitment success across medical specialities in the United Kingdom: a longitudinal analysis of NHS England data (2021–2024)
Background: Promoting equality, diversity, and inclusion (EDI) within the NHS is a key priority. While international literature suggests sexual minority individuals may be disproportionately represented in certain medical specialties, this has only been explored via questionnaires and surveys in UK postgraduate training, and not in a large, longitudinal study. This study mapped sexual minority representation across UK specialties and evaluated whether recruitment outcomes differ significantly from heterosexual counterparts. Methods: A longitudinal cohort analysis was conducted using NHS England recruitment data (2021–2024). Specialties with fewer than 500 total observations were excluded due to data suppression. Sexual minority proportions were calculated at three recruitment stages: application, offer, and acceptance. Recruitment equity was assessed using Odds Ratios (ORs) with 95% Confidence Intervals (CIs) to compare the odds of receiving an offer between sexual minority and heterosexual applicants ( p < 0.05). Results: Of 214,415 applications, 4% ( n = 7,751) identified as a sexual minority. Sexual minority applicants received 5% of offers ( n = 3,734) and accepted 5% of posts ( n = 2,740). Marked variation occurred between specialties. At entry level (ST1), sexual minority applicant proportions were highest in community sexual and reproductive health (9%), public health (7%), and histopathology (6%), and lowest in cardiothoracic surgery (2%), general practice (2%), and clinical radiology (3%). At higher level (ST3), psychiatry subspecialties (7%) and anaesthetics (5%) showed the highest representation, whereas acute internal medicine (1%) and trauma and orthopaedic surgery (1%) showed the lowest. Of the 32 specialities included after removing 21 specialities with fewer than 500 total offers, sexual minority applicants were not disadvantaged in obtaining offers. At entry level (ST1), sexual minority applicants had significantly higher odds of receiving offers in multiple specialties, notably for core psychiatry training (OR 3.4, 95% CI 3.0–4.0). At higher level (ST3), sexual minority applicants had significantly higher odds of receiving offers in acute internal medicine, haematology, trauma and orthopaedic surgery, and clinical oncology. Conclusion: UK recruitment processes provide an equitable gateway for sexual minority doctors, showing no systemic bias in offer rates. However, marked variation in representation suggests cultural perceptions or self-selection may influence career choices, highlighting a need to investigate potential structural barriers in low-representation specialties.
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2) , rkag052
Holistic management of juvenile idiopathic arthritis across all ages: British Society for Rheumatology Guideline scope
Lay Summary: What does this mean for patients? Juvenile idiopathic arthritis (JIA) is the most common type of arthritis that starts before the age of 16 years. Many children and young people (CYP) continue to be affected by JIA and may need to be on treatment when they are adults. Most CYP with JIA have swollen, stiff and painful joints for at least 6 weeks. JIA can also affect other parts of the body. This includes the skin, the places where tendons join bones (called entheses) and sometimes internal organs. Some young people may also develop inflammation in their eyes, called uveitis. If this is not treated, it can affect eyesight and could lead to sight loss. People with JIA often need medicines to control inflammation. They are usually cared for by a team of healthcare professionals called a multidisciplinary team. This team may include doctors, nurses, pharmacists, physiotherapists, occupational therapists, podiatrists, psychologists and youth workers. They work together to help manage symptoms and prevent long-term damage. The British Society for Rheumatology (BSR) is the main organisation in the UK for healthcare professionals who care for people with JIA. BSR writes guidelines that help healthcare teams provide high-quality care. These guidelines are written with input from experts and people with lived experience. They help make sure that everyone receives good care wherever they live, including during the move from child to adult services. This article explains how BSR will develop a new guideline to diagnose, treat and monitor children, young people and adults with JIA. The guideline will follow the BSR protocol for creating clinical guidelines.
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2) , rkag052
Open AccessHolistic management of juvenile idiopathic arthritis across all ages: British Society for Rheumatology Guideline scope
Lay Summary: What does this mean for patients? Juvenile idiopathic arthritis (JIA) is the most common type of arthritis that starts before the age of 16 years. Many children and young people (CYP) continue to be affected by JIA and may need to be on treatment when they are adults. Most CYP with JIA have swollen, stiff and painful joints for at least 6 weeks. JIA can also affect other parts of the body. This includes the skin, the places where tendons join bones (called entheses) and sometimes internal organs. Some young people may also develop inflammation in their eyes, called uveitis. If this is not treated, it can affect eyesight and could lead to sight loss. People with JIA often need medicines to control inflammation. They are usually cared for by a team of healthcare professionals called a multidisciplinary team. This team may include doctors, nurses, pharmacists, physiotherapists, occupational therapists, podiatrists, psychologists and youth workers. They work together to help manage symptoms and prevent long-term damage. The British Society for Rheumatology (BSR) is the main organisation in the UK for healthcare professionals who care for people with JIA. BSR writes guidelines that help healthcare teams provide high-quality care. These guidelines are written with input from experts and people with lived experience. They help make sure that everyone receives good care wherever they live, including during the move from child to adult services. This article explains how BSR will develop a new guideline to diagnose, treat and monitor children, young people and adults with JIA. The guideline will follow the BSR protocol for creating clinical guidelines.
- Open Access
- 21 July 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (3) , 118-123
Misdiagnosis and prevalence of rheumatological diseases in early inflammatory arthritis clinic: results from a UK single-centre retrospective cohort study
- 21 July 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (3) , 118-123
Open AccessMisdiagnosis and prevalence of rheumatological diseases in early inflammatory arthritis clinic: results from a UK single-centre retrospective cohort study
- Open Access
- 8 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (9) , 1469-1483
Systematic review and independent validation of genetic factors of radiographic outcome in rheumatoid arthritis identifies a genome-wide association with CARD9
- 8 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (9) , 1469-1483
Open AccessSystematic review and independent validation of genetic factors of radiographic outcome in rheumatoid arthritis identifies a genome-wide association with CARD9
- 25 June 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 2961-2966
Insomnia and short sleep duration, but not chronotype, is associated with chronic widespread pain: Mendelian randomization study
Objectives Sleep disturbance has been associated with chronic widespread pain (CWP), but their causal relationship remains unclear. We aimed to examine the causal relationship and direction between CWP and sleep traits, namely insomnia, sleep duration and chronotype, using Mendelian Randomization. Method We used genetic association data from ~0.5 million individuals and up to 1.8 million controls from the UK Biobank (UKB). All traits were defined predominantly by self-report. Short sleep duration was defined as average ≤6 hours per 24 hours. Chronotype refers to the inclination to sleep at certain times where some wake and go to bed early (‘morning’ person), and others wake and go to sleep later (‘evening’ person). To permit use of the largest available genetic association data, we used the Causal Analysis Using Summary Effect estimates (CAUSE) method, which allows for sample overlap. Results Insomnia (OR 1.009, 95% credible interval 1.005, 1.014; p = 0.018 that the causal model is a better fit than non-causal model) and short sleep duration (OR 1.060, 95%CrI 1.038, 1.083; p = 0.040) were causally associated with increased risk of CWP, with limited evidence for reverse causation. There was no evidence in support of long sleep duration or chronotype being associated with CWP. Conclusions This study suggest that insomnia and short sleep duration (≤6 hours) are associated with an increased risk of CWP. Improving short sleep duration and insomnia, rather than chronotype, may be effective in reducing the risk of CWP, although these results should be replicated in epidemiological and interventional studies.
- 25 June 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 2961-2966
Insomnia and short sleep duration, but not chronotype, is associated with chronic widespread pain: Mendelian randomization study
Objectives Sleep disturbance has been associated with chronic widespread pain (CWP), but their causal relationship remains unclear. We aimed to examine the causal relationship and direction between CWP and sleep traits, namely insomnia, sleep duration and chronotype, using Mendelian Randomization. Method We used genetic association data from ~0.5 million individuals and up to 1.8 million controls from the UK Biobank (UKB). All traits were defined predominantly by self-report. Short sleep duration was defined as average ≤6 hours per 24 hours. Chronotype refers to the inclination to sleep at certain times where some wake and go to bed early (‘morning’ person), and others wake and go to sleep later (‘evening’ person). To permit use of the largest available genetic association data, we used the Causal Analysis Using Summary Effect estimates (CAUSE) method, which allows for sample overlap. Results Insomnia (OR 1.009, 95% credible interval 1.005, 1.014; p = 0.018 that the causal model is a better fit than non-causal model) and short sleep duration (OR 1.060, 95%CrI 1.038, 1.083; p = 0.040) were causally associated with increased risk of CWP, with limited evidence for reverse causation. There was no evidence in support of long sleep duration or chronotype being associated with CWP. Conclusions This study suggest that insomnia and short sleep duration (≤6 hours) are associated with an increased risk of CWP. Improving short sleep duration and insomnia, rather than chronotype, may be effective in reducing the risk of CWP, although these results should be replicated in epidemiological and interventional studies.
- Open Access
- 17 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (5) , 696-703
Using Polygenic Risk Scores to Aid Diagnosis of Patients With Early Inflammatory Arthritis: Results From the Norfolk Arthritis Register
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image
- 17 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (5) , 696-703
Open AccessUsing Polygenic Risk Scores to Aid Diagnosis of Patients With Early Inflammatory Arthritis: Results From the Norfolk Arthritis Register
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image
- Open Access
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (1) , 188-194
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
Up to 40% of psoriatic arthritis (PsA) patients experience first-line Tumour Necrosis Factor inhibitors (TNF-i) failure. Lower serum drug levels (SDL) have been associated with lower response in autoimmune conditions. This study aimed to: (i) establish the relationship between adalimumab (ADL) and etanercept (ETN) SDL and 3-month response; and (ii) identify optimal non-trough SDL thresholds in PsA. PsA patients commencing ADL or ETN were recruited to the UK observational study OUTPASS. Patients were seen pre-TNF-i and at 3 months when response was measured, and non-trough serum samples collected. Response was defined according to the PsARC or EULAR criteria. Descriptive statistics and concentration-effect curves established differences in SDL based on response. Receiver operating characteristics and regression identified optimal SDL thresholds. PsA ETN (n = 97) PsARC and EULAR good responders had significantly higher 3-month SDL compared with non-responders (p= 0.006 and p= 0.020 respectively). Non-trough 3-month ETN SDL discriminated PsARC responders from non-responders (AUC = 0.70), with a threshold of 1.8 µg/ml being 63% specific and 69% sensitive. EULAR good and non-/moderate responders were discriminated with an AUC of 0.65 with a threshold of 2.0 µg/ml being 57% specific and 69% sensitive. ADL prescribed (n = 104) EULAR good responders had significantly higher 3-month SDL (p= 0.049). Non-trough 3-month ADL SDL discriminated EULAR good and non-/moderate responders (AUC = 0.63) with a threshold of 3.6 µg/ml being 48% specific and 81% sensitive. Higher 3-month SDL were detected in responders. Interventions to optimise SDL may improve treatment response earlier. This study suggests 3-month SDL thresholds which may be useful in clinical practice to optimise treatment response.
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (1) , 188-194
Open AccessNon-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
Up to 40% of psoriatic arthritis (PsA) patients experience first-line Tumour Necrosis Factor inhibitors (TNF-i) failure. Lower serum drug levels (SDL) have been associated with lower response in autoimmune conditions. This study aimed to: (i) establish the relationship between adalimumab (ADL) and etanercept (ETN) SDL and 3-month response; and (ii) identify optimal non-trough SDL thresholds in PsA. PsA patients commencing ADL or ETN were recruited to the UK observational study OUTPASS. Patients were seen pre-TNF-i and at 3 months when response was measured, and non-trough serum samples collected. Response was defined according to the PsARC or EULAR criteria. Descriptive statistics and concentration-effect curves established differences in SDL based on response. Receiver operating characteristics and regression identified optimal SDL thresholds. PsA ETN (n = 97) PsARC and EULAR good responders had significantly higher 3-month SDL compared with non-responders (p= 0.006 and p= 0.020 respectively). Non-trough 3-month ETN SDL discriminated PsARC responders from non-responders (AUC = 0.70), with a threshold of 1.8 µg/ml being 63% specific and 69% sensitive. EULAR good and non-/moderate responders were discriminated with an AUC of 0.65 with a threshold of 2.0 µg/ml being 57% specific and 69% sensitive. ADL prescribed (n = 104) EULAR good responders had significantly higher 3-month SDL (p= 0.049). Non-trough 3-month ADL SDL discriminated EULAR good and non-/moderate responders (AUC = 0.63) with a threshold of 3.6 µg/ml being 48% specific and 81% sensitive. Higher 3-month SDL were detected in responders. Interventions to optimise SDL may improve treatment response earlier. This study suggests 3-month SDL thresholds which may be useful in clinical practice to optimise treatment response.